NO963731L - Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister - Google Patents

Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister

Info

Publication number
NO963731L
NO963731L NO963731A NO963731A NO963731L NO 963731 L NO963731 L NO 963731L NO 963731 A NO963731 A NO 963731A NO 963731 A NO963731 A NO 963731A NO 963731 L NO963731 L NO 963731L
Authority
NO
Norway
Prior art keywords
antagonists
obsessive
treatment
compulsive diseases
compulsive
Prior art date
Application number
NO963731A
Other languages
English (en)
Norwegian (no)
Other versions
NO963731D0 (no
Inventor
Christopher Joseph Schmidt
John Herr Kehne
Robert Andrew Padich
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of NO963731D0 publication Critical patent/NO963731D0/no
Publication of NO963731L publication Critical patent/NO963731L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO963731A 1994-03-09 1996-09-06 Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister NO963731L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/209,084 US5618824A (en) 1994-03-09 1994-03-09 Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
PCT/US1995/001306 WO1995024194A1 (fr) 1994-03-09 1995-02-01 Traitement de psychonevroses obsessionnelles au moyen d'antagonistes de 5-ht¿2?

Publications (2)

Publication Number Publication Date
NO963731D0 NO963731D0 (no) 1996-09-06
NO963731L true NO963731L (no) 1996-11-06

Family

ID=22777257

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963731A NO963731L (no) 1994-03-09 1996-09-06 Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister

Country Status (15)

Country Link
US (1) US5618824A (fr)
EP (1) EP0749309A1 (fr)
JP (1) JP3861250B2 (fr)
KR (1) KR100360132B1 (fr)
CN (1) CN1143321A (fr)
AU (1) AU690968B2 (fr)
CA (1) CA2183954C (fr)
FI (1) FI963511A0 (fr)
HU (1) HU218948B (fr)
IL (1) IL112895A (fr)
NO (1) NO963731L (fr)
NZ (1) NZ281768A (fr)
TW (1) TW301606B (fr)
WO (1) WO1995024194A1 (fr)
ZA (1) ZA951797B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
EP0796619A1 (fr) 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Utilisation de (+)-alpha-(2,3-diméthoxyphényle)-1-(2-(4-fluorophényle)éthyle)-4-pipéridineméthanol pour le traitement des troubles dépressifs et bipolaires
EP0891299B1 (fr) 1996-04-05 2000-08-16 Fmc Corporation PROCEDE DE PREPARATION DE COMPOSES SPINELLES INTERCALAIRES Li(1+x)Mn(2-x)O(4+y)
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
SE9801516D0 (sv) * 1998-04-30 1998-04-30 Maria Carlsson M100907/4-Piperidinemethanol derivatives for autism
EA003791B1 (ru) * 1998-08-28 2003-10-30 Авентис Фармасьютикалз Инк. Способ лечения больного с расстройством сна
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL147310A0 (en) * 1999-07-16 2002-08-14 Aventis Pharma Inc Sulfuric acid mono-[3-({1-[2-(4-fluoro-phenyl)-ethyl}-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl] ester
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
US8629301B2 (en) * 2004-11-22 2014-01-14 Mallinckrodt Llc Process for the purification of benzphetamine hydrochloride
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
WO2017214442A1 (fr) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Procédés et compositions pour réduire le dysfonctionnement tactile et l'anxiété associés au trouble du spectre de l'autisme, au syndrome de rett et au syndrome de l'x fragile
CA3099751A1 (fr) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions et procedes permettant de reduire un dysfonctionnement tactile, l'anxiete et une deficience sociale
AU2019279858A1 (en) 2018-05-29 2020-11-26 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
WO2020237043A1 (fr) * 2019-05-22 2020-11-26 President And Fellows Of Harvard College Test d'inhibition de pré-impulsion tactile humaine
WO2021261471A1 (fr) * 2020-06-23 2021-12-30 国立大学法人京都大学 Substance thérapeutique pour trouble obsessionnel compulsif

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
EP0436245A1 (fr) * 1989-12-27 1991-07-10 Duphar International Research B.V Benzimidazol-2(1H)-ones-3,4-pontées et substituées
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5264576A (en) * 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
WO1994014801A1 (fr) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Derives heterocycliques de l'uree antagonistes de 5ht2c et 5h¿2b?
US6087346A (en) * 1993-06-23 2000-07-11 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JP3861250B2 (ja) 2006-12-20
HUT75317A (en) 1997-05-28
CA2183954A1 (fr) 1995-09-14
FI963511L (fi) 1996-09-06
ZA951797B (en) 1996-12-03
WO1995024194A1 (fr) 1995-09-14
KR970701544A (ko) 1997-04-12
EP0749309A1 (fr) 1996-12-27
NZ281768A (en) 2001-02-23
CN1143321A (zh) 1997-02-19
IL112895A (en) 1999-12-31
CA2183954C (fr) 2000-07-18
FI963511A7 (fi) 1996-09-06
AU690968B2 (en) 1998-05-07
NO963731D0 (no) 1996-09-06
AU1869495A (en) 1995-09-25
JPH09510441A (ja) 1997-10-21
HU9602449D0 (en) 1996-11-28
TW301606B (fr) 1997-04-01
FI963511A0 (fi) 1996-09-06
HU218948B (hu) 2001-01-29
US5618824A (en) 1997-04-08
KR100360132B1 (ko) 2003-08-02
IL112895A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
CA2183954A1 (fr) Traitement de troubles obsessivo-compulsifs a l'aide d'antagonistes de 5-ht2
AU3492895A (en) Novel substituted piperidines useful for the treatment of allergic diseases
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
DE69105501D1 (de) (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
NO20005454D0 (no) Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmÕte for fremstilling derav
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
NO964871L (no) Nye agonistforbindelser
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
WO2001098268A3 (fr) Amides de piperidine utilises comme modulateurs de l'activite des recepteurs des chimiokines
WO1999026932A8 (fr) Derives heterocycliques substitues par un groupe amidino et leur utilisation en tant qu'anticoagulants
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
TR199700956T1 (xx) Indazolkarboksamidler.
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AP2000002017A0 (en) Salts of paroxetine.
WO2001089498A3 (fr) Utilisation de (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4piperidinemethanol ou ses promedicaments dans le traitement de patients pour des symptomes de demence et de psychose provoquee par la dopamine.
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application